Genomic analysis of SARS-CoV-2 breakthrough infections from Varanasi, India

Zaveri, L.; Singh, R.; Basu, P.; Banu, S.; Mukherjee, P.; Vishwakarma, S.; Sahni, C.; Kaur, M.; Singh, N. K.; Yadav, A. K.; Ashish, A.; Mishra, S.; Tiwari, S.; Mishra, S. P.; Vodapalli, A.; Bollu, H.; Das, D.; Singh, P. P.; Chaubey, G.; Sowpati, D. T.; Tallapaka, K. B.

Studies worldwide have shown that the available vaccines are highly effective against SARS-CoV-2. However, there are growing laboratory reports that the newer variants of concerns (VOCs e.g. Alpha, Beta, Delta etc) may evade vaccine induced defense. In addition to that, there are few ground reports on health workers having breakthrough infections. In order to understand VOC driven breakthrough infection we investigated 14 individuals who tested positive for SARS-CoV-2 after being administered a single or double dose of Covishield (ChAdOx1, Serum Institute of India) from the city of Varanasi, which is located in the Indian state of Uttar Pradesh. Genomic analysis revealed that 78.6% (11/14) of the patients were infected with the B.1.617.2 (Delta) variant. Notably, the frequency (37%) of this variant in the region was significantly lower (p<0.01), suggesting that the vaccinated people were asymmetrically infected with the Delta variant. Most of the patients tested displayed mild symptoms, indicating that even a single dose of the vaccine can help in reducing the severity of the disease. However, more comprehensive epidemiological studies are required to understand the effectiveness of vaccines against the newer VOCs.